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Introduction
The following abstract is part of an ongoing series of
articles produced by the Cochrane Collaborative
Review Group on Peripheral Vascular Diseases,
which is part of the Cochrane Collaboration. The
review is published in full on ‘The Cochrane Library’,
a quarterly electronic journal available on CD-ROM
and via the Internet. The electronic format allows
Cochrane reviews to accommodate new data as they
become available, making the library a consistently
up-to-date source of information over time.
Certain abstracts appearing on the Cochrane
Library may be presented in a simpler, less scientific
format than the abstract presented here to permit
greater accessibility to the public. However, the
substance of both versions is the same. Cochrane
reviews are now indexed on MEDLINE.
If you are interested in writing a Cochrane review
or contributing to the activities of the Cochrane
Peripheral Vascular Diseases Group please contact:
Professor F. G. R. Fowkes








Any comments or criticisms on Cochrane reviews/
abstracts should be made through the comments/
criticisms facility on the Cochrane Library, or by
contacting the group at the above address.
Abstract. Dressings and Topical Agents for Arterial
Leg Ulcers
E. A. Nelson and M. D. Bradley
Date of most recent substantive amendment: 22 October
2002
Background
It is estimated that people in industrialised countries
have a 1% chance of suffering from a leg ulcer at some
time in their life. The majority of leg ulcers are
associated with circulation problems: poor blood
return in the veins causes venous ulcers (around 70%
of ulcers) and poor blood supply to the legs causes
arterial ulcers (around 25% of ulcers). Treatment of
arterial leg ulcers is directed towards correcting the
poor arterial blood supply, for example, by surgically
correcting arterial blockages, and by supporting ulcer
healing using topical agents (medicines in cream/oint-
ment) and wound dressings. There are a large number
of topical agents and wound dressings available and it
is unclear what impact these have on ulcer healing.
Objectives
To determine whether topical agents and wound
dressings affect the rate of healing in arterial ulcers.
To compare healing rates, costs and patient-centred
outcomes between wound dressings and topical
agents.
Search strategy
Publications describing (or potentially describing)
randomised controlled trials (RCTs), or controlled
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clinical trials (CCTs), of dressings and topical agents
for arterial leg ulcers were sought through the
Specialised Trials Registers of the Cochrane Wounds
Group (last searched January 2002) and the Cochrane
Peripheral Vascular Diseases Group (last searched
April 2002).
Selection criteria
RCTs or CCTs (trials with non-randomised concurrent
comparison groups) were eligible for inclusion. The
participants had to have ulcers that were described as
arterial, and the time to healing, proportion comple-
tely healed, or rate of reduction in ulcer area had to be
reported. All wound dressings and topical agents were
eligible for inclusion in this review.
Data collection & analysis
Information on the participants’ characteristics, the
interventions, and outcomes, as well as data on the
trial methods, such as blinding of patients and
clinicians, and allocation concealment were extracted
using a standardised data extraction form.
Main results
One trial met the inclusion criteria. This small trial
compared ketanserin ointment with vehicle alone,
changed twice a day. The trial was too small and had
too short a follow-up period to be able to determine
whether there was any difference in healing rates.
Reviewers’ conclusions
There is insufficient evidence to determine whether
the choice of topical agent or dressing affects the
healing of arterial leg ulcers. Inadequate description of
the people in the one included trial means that the
results cannot be easily applied to other clinical
populations.
Abstract. Medical Adjuvant Treatment to Increase
Patency of Arteriovenous Fistulae and Grafts
A. F. Da Silva, X. Escofet and P. A. Rutherford
Date of most recent substantive amendment: 24 July
2002
Background
End stage renal failure (ESRF) patients often require
either the formation of an arteriovenous (A-V) fistula
or an A-V interposition prosthetic shunt for
haemodialysis.
Objectives
To determine the effects of adjuvant drug treatment on
the patency of fistulae and shunts in patients with
ESRF undergoing haemodialysis, by assessing the
number of thrombotic episodes.
Search strategy
Publications describing (or potentially describing),
randomised controlled trials of medical adjuvant
treatment of patients with ESRF on haemodialysis
via A-V fistula or interposition prosthetic A-V shunt,
were sought through electronic searches of the
Cochrane Peripheral Vascular Diseases Specialised
Trials Register (last searched October 2002), and the
Cochrane Central Register of Controlled Trials (CEN-
TRAL) database (last searched Issue 3, 2002).
Selection criteria
Randomised controlled trials of active drug versus
placebo in patients with ESRF undergoing haemodia-
lysis via an A-V fistula or prosthetic interposition A-V
shunt.
Data collection & analysis
Two of the reviewers (ADS, PAR), independently
assessed trial quality and all three extracted data. The
patency rate of the long term fistula or shunt was the
main outcome measure analysed. Information on
adverse events was also collected from the trials.
Main results
The overall search identified three randomised
controlled trials of aspirin versus placebo with a total
number of 173 participants followed up to a maximum
of 18 months. The aspirin dosage was different in each
of the trials (325 mg/once daily; 500 mg/once daily;
and 160 mg/once daily). The overall result of the
meta-analysis favoured treatment with aspirin (Odds
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Ratio (OR) 0.42, 95% confidence interval (CI) 0.20–0.86).
The overall p-value for the three studies was 0.02.
Three trials comparing ticlopidine versus placebo
were also identified with a total number of 312
participants. All patients were followed up for one
month, and the dose of ticlopidine given was the same
for all three studies (250 mg/twice daily). The overall
result of this meta-analysis also favoured treatment
(OR ¼ 0.47, 95% CI 0.26 to 0.85). P-value for overall
effect was 0.01.
One trial using a parallel group design examined
the effect of dipyridamole versus placebo, and
dipyridamole plus aspirin versus placebo. Patients
were followed up for 18 months. The overall result
favoured treatment for both groups (OR 0.29, 95% CI
0.06 to 1.40) for dipyridamole versus placebo and (OR
0.77, CI 0.19 to 3.19) for dipyridamole plus aspirin
versus placebo.
Reviewers’ conclusions
These meta-analyses confirm the beneficial effect of
antiplatelet treatment as an adjuvant to increase the
patency of A-V fistulae and shunts in the short term.
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